Fundamental dimension Equity attribute | DLOCPeer $0.00010.00% Cap $73.38KP/E -0.0x QuantScore36/100 | BNIGFPeer $0.00640.00% Cap $217.5KP/E -0.1x QuantScore39/100 | CIRXLeader $0.02130.00% Cap $105.3KP/E 0.0x QuantScore54/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
43/100 |
56/100 |
31/100 |
Valuation Multiples, PEG & DCF upside | 33/100 | 0/100 | 75/100 |
Health Piotroski, Altman Z, leverage & liquidity | 20/100 | 24/100 | 30/100 |
Growth Revenue / earnings growth & margins | 46/100 | 75/100 | 82/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -0.0x | -0.1x | 0.0x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | -0.2x | -1.1x | 8.3x |
Price / Sales | 2.8x | 1.0x | 0.0x |
Price / Free Cash Flow | -0.1x | -0.1x | -0.2x |
PEG ratio | 0.00 | -0.00 | 0.00 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 1 / 9 | 3 / 9 | 5 / 9 |
Altman Z-Score | -2586.21 (Distress) | -12.23 (Distress) | -39.35 (Distress) |
Total debt / equity | -0.28 | 0.90 | -0.15 |
Quick ratio | 0.0x | 1.2x | 0.1x |
Interest coverage | -4.0x | — | 0.7x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | +12.0% | +101.5% | +141.1% |
Net income growth YoY | -587.4% | +60.2% | +73.3% |
Gross margin (TTM) | 100.0% | 98.4% | 46.9% |
Operating margin (FY) | -15220.9% | -737.1% | -4.1% |
FCF margin (FY) | -4078.0% | -371.5% | -42.8% |
5. Trailing price performancePrice change over period |
1M return | +0.0% | 0.0% | -14.1% |
3M return | +0.0% | 0.0% | -29.0% |
6M return | +0.0% | 0.0% | -24.2% |
Year to date | +0.0% | 0.0% | -50.5% |
1Y return | +0.0% | 0.0% | +51.1% |
3Y return | -85.7% | -99.9% | -3.2% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $-0.0012 -1348.0% premium | $-0.24 -3850.5% premium | $-8.76 -41237.3% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |